Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
Phase 3b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Chronic Constipation and Prominent Abdominal Bloating at Baseline
1 other identifier
interventional
487
2 countries
151
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of linaclotide compared with placebo in patients with chronic constipation (CC) and prominent abdominal bloating. This study includes an up to 3-week screening period and a 2-3 week pretreatment period. Patients who are eligible will be randomized to one of two doses of linaclotide or placebo for 12 weeks. This 12-week study will assess the effects of linaclotide on bowel movement frequency, as well as other abdominal and bowel symptoms of CC.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Aug 2012
Shorter than P25 for phase_3
151 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 13, 2012
CompletedFirst Posted
Study publicly available on registry
July 17, 2012
CompletedStudy Start
First participant enrolled
August 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2013
CompletedResults Posted
Study results publicly available
April 26, 2016
CompletedApril 26, 2016
March 1, 2016
9 months
July 13, 2012
May 29, 2014
March 24, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
9/12 Week Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder
A 9/12 Week CSBM 3+1 Responder is a patient who is a CSBM 3+1 Weekly Responder for at least 9 out of the 12 weeks of the Treatment Period. A CSBM 3+1 Weekly Responder is a patient who had a CSBM Weekly Frequency Rate that was 3 or greater and increased by 1 or more from baseline.
12-week treatment period
Secondary Outcomes (23)
9/12 Week Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder
12-week treatment period
Change From Baseline in 12-Week Abdominal Bloating
Baseline and 12-week treatment period
Percent Change From Baseline in 12-week Abdominal Bloating
Baseline and 12-week treatment period
Percent Change From Baseline in Abdominal Bloating at Week 12
Baseline and Week 12
6/12 Week Abdominal Bloating 30% Responder
12-week treatment period
- +18 more secondary outcomes
Study Arms (3)
Linaclotide 290 micrograms
EXPERIMENTALLinaclotide 290 micrograms
Linaclotide 145 Micrograms
EXPERIMENTALLinaclotide 145 micrograms
Placebo
PLACEBO COMPARATORMatching placebo
Interventions
oral capsule, taken once daily each morning at least 30 minutes before breakfast
oral capsule, taken once daily each morning at least 30 minutes before breakfast
oral capsule, taken once daily each morning at least 30 minutes before breakfast
Eligibility Criteria
You may qualify if:
- Patient has completed a colonoscopy according to the American Gastroenterological Association criteria with no clinically significant findings
- Patient has successfully completed protocol procedures (with no clinically significant findings)
- Patient meets protocol criteria for Chronic Constipation(CC): \< 3 bowel movements per week and reports one or more of the following symptoms for at least 12 weeks:
- Straining during more than 25% of BMs
- Lumpy or hard stools during more than 25% of BMs
- Sensation of incomplete evacuation during more than 25% of BMs
- Patient demonstrates continued chronic constipation and bloating through Pretreatment Period
- Patient is compliant with Interactive voice response System (IVRS)
You may not qualify if:
- Patient has a history of loose or watery stools
- Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS)
- Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility
- Patient has any protocol-excluded or clinically significant medical or surgical history that would limit the patient's ability to complete or participate in this clinical trial or could confound the study assessments
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Forest Laboratorieslead
- Ironwood Pharmaceuticals, Inc.collaborator
Study Sites (151)
Forest Investigative Site 020
Chandler, Arizona, 85224, United States
Forest Investigative Site 102
Chandler, Arizona, 85224, United States
Forest Investigative Site 149
Glendale, Arizona, 85308, United States
Forest Investigative Site 126
Goodyear, Arizona, 85395, United States
Forest Investigative Site 018
Phoenix, Arizona, 85018, United States
Forest Investigative Site 061
Phoenix, Arizona, 85020, United States
Forest Investigative Site 022
Scottsdale, Arizona, 85251, United States
Forest Investigative Site 079
Tucson, Arizona, 85704, United States
Forest Investigative Site 071
Tucson, Arizona, 85712, United States
Forest Investigative Site 135
North Little Rock, Arkansas, 72117, United States
Forest Investigative Site 106
Anaheim, California, 92801, United States
Forest Investigative Site 104
Laguna Hills, California, 92653, United States
Forest Investigative Site 066
Mission Hills, California, 91345, United States
Forest Investigative Site 095
San Carlos, California, 94070, United States
Forest Investigative Site 009
San Diego, California, 92108, United States
Forest Investigative Site 151
Santa Monica, California, 90404, United States
Forest Investigative Site 010
Westlake Village, California, 91361, United States
Forest Investigative Site 012
Boulder, Colorado, 80304, United States
Forest Investigative Site 041
Colorado Springs, Colorado, 80904, United States
Forest Investigative Site 045
Colorado Springs, Colorado, 80907, United States
Forest Investigative Site 060
Longmont, Colorado, 80501, United States
Forest Investigative Site 007
Bristol, Connecticut, 06010, United States
Forest Investigative Site 153
Waterbury, Connecticut, 06708, United States
Forest Investigative Site 091
Boynton Beach, Florida, 33426, United States
Forest Investigative Site 047
Bradenton, Florida, 34208, United States
Forest Investigative Site 042
Brooksville, Florida, 34601, United States
Forest Investigative Site 133
Coral Gables, Florida, 33134, United States
Forest Investigative Site 131
DeLand, Florida, 32720, United States
Forest Investigative Site 051
Fort Myers, Florida, 33916, United States
Forest Investigative Site 137
Inverness, Florida, 34452, United States
Forest Investigative Site 114
Jacksonville, Florida, 32205, United States
Forest Investigative Site 004
Jupiter, Florida, 33458, United States
Forest Investigative Site 016
Kissimmee, Florida, 34741, United States
Forest Investigative Site 097
Lauderdale Lakes, Florida, 33319, United States
Forest Investigative Site 003
Miami, Florida, 33143, United States
Forest Investigative Site 002
Miami, Florida, 33183, United States
Forest Investigative Site 130
New Smyrna Beach, Florida, 32168, United States
Forest Investigative Site 040
Ocala, Florida, 34471, United States
Forest Investigative Site 083
Orlando, Florida, 32806, United States
Forest Investigative Site 150
Oviedo, Florida, 32765, United States
Forest Investigative Site 132
Port Orange, Florida, 32129, United States
Forest Investigative Site 127
Seminole, Florida, 33777, United States
Forest Investigative Site 087
St. Petersburg, Florida, 33709, United States
Forest Investigative Site 064
Tampa, Florida, 33606, United States
Forest Investigative Site 115
Zephyrhills, Florida, 33542, United States
Forest Investigative Site 021
Marietta, Georgia, 30060, United States
Forest Investigative Site 011
Marietta, Georgia, 30067, United States
Forest Investigative Site 109
Sandy Springs, Georgia, 30328, United States
Forest Investigative Site 037
Stockbridge, Georgia, 30281, United States
Forest Investigative Site 023
Woodstock, Georgia, 30189, United States
Forest Investigative Site 015
Idaho Falls, Idaho, 83404, United States
Forest Investigative Site 122
Peoria, Illinois, 61602, United States
Forest Investigative Site 043
Rockford, Illinois, 61107, United States
Forest Investigative Site 107
Anderson, Indiana, 46011, United States
Forest Investigative Site 117
Clive, Iowa, 50325, United States
Forest Investigative Site 146
Clive, Iowa, 50325, United States
Forest Investigative Site 143
Davenport, Iowa, 52807, United States
Forest Investigative Site 055
Iowa City, Iowa, 52242, United States
Forest Investigative Site 028
Newton, Kansas, 67114, United States
Forest Investigative Site 112
Overland Park, Kansas, 66215, United States
Forest Investigative Site 034
Wichita, Kansas, 67205, United States
Forest Investigative Site 032
Wichita, Kansas, 67207, United States
Forest Investigative Site 128
Lexington, Kentucky, 40509, United States
Forest Investigative Site 134
Madisonville, Kentucky, 42431, United States
Forest Investigative Site 121
Baton Rouge, Louisiana, 70809, United States
Forest Investigative Site 124
Metairie, Louisiana, 70006, United States
Forest Investigative Site 101
Monroe, Louisiana, 71201, United States
Forest Investigative Site 058
Shreveport, Louisiana, 71101, United States
Forest Investigative Site 099
Shreveport, Louisiana, 71103, United States
Forest Investigative Site 062
Baltimore, Maryland, 21215, United States
Forest Investigative Site 008
Chevy Chase, Maryland, 20815, United States
Forest Investigative Site 014
Hagerstown, Maryland, 21742, United States
Forest Investigative Site 024
Towson, Maryland, 21286, United States
Forest Investigative Site 006
Boston, Massachusetts, 02135, United States
Forest Investigative Site 070
Chesterfield, Michigan, 48047, United States
Forest Investigative Site 145
Traverse City, Michigan, 49684, United States
Forest Investigative Site 141
Jackson, Mississippi, 39202, United States
Forest Investigative Site 077
Fremont, Nebraska, 68025, United States
Forest Investigative Site 048
Omaha, Nebraska, 68134, United States
Forest Investigative Site 052
Henderson, Nevada, 89014, United States
Forest Investigative Site 080
Las Vegas, Nevada, 89121, United States
Forest Investigative Site 036
Clifton, New Jersey, 07012, United States
Forest Investigative Site 088
Marlton, New Jersey, 08053, United States
Forest Investigative Site 033
Vineland, New Jersey, 08360, United States
Forest Investigative Site 063
Albuquerque, New Mexico, 87106, United States
Forest Investigative Site 093
Albuquerque, New Mexico, 87108, United States
Forest Investigative Site 044
Brooklyn, New York, 11206, United States
Forest Investigative Site 017
Great Neck, New York, 11021, United States
Forest Investigative Site 142
Asheboro, North Carolina, 27203, United States
Forest Investigative Site 094
Asheville, North Carolina, 28801, United States
Forest Investigative Site 075
Boone, North Carolina, 28607, United States
Forest Investigative Site 123
Chapel Hill, North Carolina, 27599-7080, United States
Forest Investigative Site 140
Davidson, North Carolina, 28036, United States
Forest Investigative Site 039
Fayetteville, North Carolina, 28304, United States
Forest Investigative Site 031
Greensboro, North Carolina, 27403, United States
Forest Investigative Site 029
Greensboro, North Carolina, 27408, United States
Forest Investigative Site 078
Greensboro, North Carolina, 27408, United States
Forest Investigative Site 084
Harrisburg, North Carolina, 28075, United States
Forest Investigative Site 073
Hickory, North Carolina, 28601, United States
Forest Investigative Site 050
Hickory, North Carolina, 28602, United States
Forest Investigative Site 139
High Point, North Carolina, 27262, United States
Forest Investigative Site 027
Raleigh, North Carolina, 27612, United States
Forest Investigative Site 119
Statesville, North Carolina, 28625, United States
Forest Investigative Site 089
Wilmington, North Carolina, 28401, United States
Forest Investigative Site 074
Winston-Salem, North Carolina, 27103, United States
Forest Investigative Site 025
Cincinnati, Ohio, 45242, United States
Forest Investigative Site 120
Cincinnati, Ohio, 45249, United States
Forest Investigative Site 056
Cleveland, Ohio, 44122, United States
Forest Investigative Site 026
Columbus, Ohio, 43215, United States
Forest Investigative Site 098
Dayton, Ohio, 45415, United States
Forest Investigative Site 090
Dayton, Ohio, 45432, United States
Forest Investigative Site 085
Mentor, Ohio, 44060, United States
Forest Investigative Site 068
Wadsworth, Ohio, 44281, United States
Forest Investigative Site 118
Oklahoma City, Oklahoma, 73104, United States
Forest Investigative Site 081
Levittown, Pennsylvania, 19056, United States
Forest Investigative Site 001
Pittsburgh, Pennsylvania, 15206, United States
Forest Investigative Site 110
Reading, Pennsylvania, 19606, United States
Forest Investigative Site 116
Greer, South Carolina, 29650, United States
Forest Investigative Site 046
Simpsonville, South Carolina, 29681, United States
Forest Investigative Site 092
Dakota Dunes, South Dakota, 57049, United States
Forest Investigative Site 129
Chattanooga, Tennessee, 37421, United States
Forest Investigative Site 138
Kingsport, Tennessee, 37660, United States
Forest Investigative Site 125
Austin, Texas, 78756, United States
Forest Investigative Site 035
Dallas, Texas, 75231, United States
Forest Investigative Site 005
Dallas, Texas, 75234, United States
Forest Investigative Site 111
Fort Worth, Texas, 76135, United States
Forest Investigative Site 100
Houston, Texas, 77034, United States
Forest Investigative Site 067
Katy, Texas, 77450, United States
Forest Investigative Site 049
Pasadena, Texas, 77505, United States
Forest Investigative Site 030
San Antonio, Texas, 78209, United States
Forest Investigative Site 076
San Antonio, Texas, 78229, United States
Forest Investigative Site 065
Sugarland, Texas, 77479, United States
Forest Investigative Site 019
Ogden, Utah, 84405, United States
Forest Investigative Site 105
Salt Lake City, Utah, 84107, United States
Forest Investigative Site 113
Sandy City, Utah, 84094, United States
Forest Investigative Site 053
Charlottesville, Virginia, 22911, United States
Forest Investigative Site 108
Chesapeake, Virginia, 23320, United States
Forest Investigative Site 136
Chesapeake, Virginia, 23320, United States
Forest Investigative Site 148
Christiansburg, Virginia, 24073, United States
Forest Investigative Site 072
Lynchburg, Virginia, 24502, United States
Forest Investigative Site 069
Newport News, Virginia, 23606, United States
Forest Investigative Site 013
Norfolk, Virginia, 23502, United States
Forest Investigative Site 038
Richmond, Virginia, 23294, United States
Forest Investigative Site 103
Spokane, Washington, 99208, United States
Forest Investigative Site 082
La Crosse, Wisconsin, 54601, United States
Forest Investigative Site 096
Milwaukee, Wisconsin, 53215, United States
Forest Investigative Site 054
Greater Sudbury, Ontario, P3E 1H5, Canada
Forest Investigative Site 059
Sarnia, Ontario, N7T 4X3, Canada
Forest Investigative Site 086
Toronto, Ontario, M4S 1Y2, Canada
Forest Investigative Site 147
Toronto, Ontario, M9W 4L6, Canada
Forest Investigative Site 152
Vaughan, Ontario, L4L 4Y7, Canada
Related Publications (2)
Lacy BE, Shea EP, Manuel M, Abel JL, Jiang H, Taylor DCA. Lessons learned: Chronic idiopathic constipation patient experiences with over-the-counter medications. PLoS One. 2021 Jan 11;16(1):e0243318. doi: 10.1371/journal.pone.0243318. eCollection 2021.
PMID: 33428631DERIVEDLacy BE, Schey R, Shiff SJ, Lavins BJ, Fox SM, Jia XD, Blakesley RE, Hao X, Cronin JA, Currie MG, Kurtz CB, Johnston JM, Lembo AJ. Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial. PLoS One. 2015 Jul 29;10(7):e0134349. doi: 10.1371/journal.pone.0134349. eCollection 2015.
PMID: 26222318DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Steven Shiff, Executive Director, Clinical Development
- Organization
- Forest Research Institute
Study Officials
- STUDY DIRECTOR
Steven Shiff, MD
Forest Laboratories
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 13, 2012
First Posted
July 17, 2012
Study Start
August 1, 2012
Primary Completion
May 1, 2013
Study Completion
August 1, 2013
Last Updated
April 26, 2016
Results First Posted
April 26, 2016
Record last verified: 2016-03